expression of granzyme b, heat shock protein 27, and tumor-associated macrophage as predictors of anthracycline-based neoadjuvant chemotherapy response through a subtype approach to local advanced breast cancer

Systemic therapy as a part of the management of locally advanced breast cancer (labc) remains a problem because the response varies. clinical, pathological, or biomolecular markers used as predictor factors for response to chemotherapy at present were not yet established or constantly practiced. the aim of this study was to investigate the relationship among granzyme b expression, tumor-associated macrophage (tam), heat shock protein 27 (hsp27), and subtypes of breast cancer patients with labc as a predictor of response to anthracycline-based neoadjuvant chemotherapy. it was an observational-analytic study. sixty patients with labc were recruited for this study. all received 3-4 series of neoadjuvant chemotherapy using anthracycline at a 3-week interval. overexpression of granzyme b, hsp27, and tam were found at 29, 31, and 27, respectively. of the twenty-nine patients with overexpression of granzyme b, only 14 respond to anthracycline-based neoadjuvant chemotherapy. of the 31 patients with overexpression of hsp 27, only 12 respond to anthracycline-based neoadjuvant chemotherapy. there are 29 patients with overexpression of granzyme b, but only 14 respond to anthracycline-based neoadjuvant chemotherapy. there are 27 patients with overexpression of tam, but only 13 respond to anthracycline-based neoadjuvant chemotherapy. overexpression of granzyme b, low expression of tam, low expression of hsp27, and different subtypes of breast cancer have not been shown as predictors of response to anthracycline-based neoadjuvant chemotherapy for locally advanced breast cancer. granzyme b, hsp27, and tam expressions were not affected by the breast cancer subtype.